Watch BIO. Know when insiders buy.
One email the day a filing lands. Free.
BIO
BIO-RAD LABORATORIES, INC.
380.12
−5.99 −1.55%
USD · close Sep 8
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
66
PASS · shorts 66
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $10.5BP/E 47.6DIV YIELD —FCF YIELD 3.36%REV TTM $2.6B +1.4%NET INCOME $222.4M −30.3%NET DEBT $686.7M52W 241.71 – 390.34SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $651M | −0.1% | 53.1% | $72.6M | $371.4M | +16.9% | 13.85 | $98.7M | $32M | $66.7M | Aug 4 |
| Q1 2026 · Mar 31 | $592.1M | +1.1% | 52.3% | $34.1M | −$527.1M | −923.6% | -19.55 | $108.1M | $30M | $78.1M | Aug 4 |
| Q4 2025 · Dec 31derived | $693.2M | +3.9% | 49.8% | −$118.9M | $720M | — | 26.39 | $164.9M | $45.8M | $119.1M | Feb 13 |
| Q3 2025 · Sep 30 | $653M | +0.5% | 52.6% | $65.3M | −$341.9M | −152.3% | -12.70 | $120.9M | $31.7M | $89.2M | Oct 29 |
| Q2 2025 · Jun 30 | $651.6M | +2.1% | 53.0% | $77.1M | $317.8M | — | 11.67 | $116.5M | $45.7M | $70.8M | Aug 4 |
| Q1 2025 · Mar 31 | $585.4M | −4.2% | 52.3% | $23.7M | $64M | −83.3% | 2.29 | $129.9M | $34.4M | $95.5M | Aug 4 |
| Q4 2024 · Dec 31 | $667.5M | −2.0% | 51.2% | $58.3M | −$715.8M | −304.7% | -25.57 | $124.2M | $42.9M | $81.3M | Feb 13 |
| Q3 2024 · Sep 30 | $649.7M | +2.8% | 54.8% | $64.5M | $653.2M | +514.5% | 23.34 | $163.6M | $40.2M | $123.4M | Oct 29 |
| Q2 2024 · Jun 30 | $638.5M | — | 55.6% | $101.5M | −$2.2B | — | -76.26 | $97.6M | $42.3M | $55.3M | Oct 29 |
| Q1 2024 · Mar 31 | $610.8M | — | 53.4% | $44.6M | $383.9M | — | 13.45 | $69.8M | $40.2M | $29.6M | Oct 29 |
| Q4 2023 · Dec 31 | $681.1M | — | 53.8% | $95.3M | $349.7M | — | 12.14 | $81M | $42.3M | $38.7M | Feb 13 |
| Q3 2023 · Sep 30 | $632.1M | — | 53.1% | $90.9M | $106.3M | — | 3.64 | $97.7M | $44.1M | $53.6M | Feb 14 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $2.6B | 51.9% | $47.2M | $759.9M | 29.4% | 27.85 | $532.2M | $157.6M | $374.6M | $295.5M | — |
| FY2024 · to Dec 31 | $2.6B | 53.7% | $269M | −$1.8B | -71.9% | -65.36 | $455.2M | $165.6M | $289.6M | $203.6M | — |
| FY2023 · to Dec 31 | $2.7B | 53.4% | $337.8M | −$637.3M | -23.9% | -21.82 | $374.9M | $156.7M | $218.2M | $428.7M | — |
| FY2022 · to Dec 31 | $2.8B | 55.9% | $482.6M | −$3.6B | -129.5% | -121.79 | $194.4M | $112.8M | $81.6M | $215.7M | — |
| FY2021 · to Dec 31 | $2.9B | 56.1% | $500.3M | $4.3B | 145.6% | 140.83 | $669.5M | $133.7M | $535.7M | $50M | — |
| FY2020 · to Dec 31 | $2.5B | 56.5% | $421.3M | $3.8B | 149.8% | 126.47 | $585M | $108.6M | $476.4M | $100M | — |
Every number comes from BIO-RAD LABORATORIES, INC.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.